1. Medtech Insight

M&A Analysis: January, Crisp Start To The Year

 
• By Catherine Longworth

2018 kicked off with 17 medtech M&A deals in January, an increase from the 12 transactions recorded in the same period last year. The month also saw major medtech players reel in some significant acquisitions.

Merging Business Network-Business leaders in global agreement

2018 kicked off with 17 medtech M&A deals in January and a wave of early activity from the big players. Deal volume was up from the 12 transactions recorded January last year, but down from the 24 deals in December 2017. The year-end flurry of activity rounded off a busy 2017 for medtech M&A with the number of acquisitions for the year exceeding that of 2016. (See Figure 1.)

Open Media

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By Shubham Singh

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.